The growing prevalence of cardiovascular and thrombotic disorders is driving strong demand for D-dimer testing. As blood clot-related risk factors continue to increase, the need for precise diagnostic tools becomes essential. Moreover, intensified research and development efforts, coupled with collaborations among major industry players, are propelling innovations in D-dimer testing methods.
LAS VEGAS , Nov. 11, 2024 /PRNewswire/ -- DelveInsight's D-Dimer Testing Market Insights report provides the current and forecast market analysis, individual leading D-dimer testing companies' market shares, challenges, D-dimer testing market drivers, barriers, trends, and key market D-dimer testing companies in the market. Key Takeaways from the D-Dimer Testing Market Report As per DelveInsight estimates, North America is anticipated to dominate the global D-dimer testing market during the forecast period.
In the D-dimer testing market, the instruments category is projected to capture a substantial revenue share in 2023. Notable D-dimer testing companies such as F. Hoffmann-La Roche Ltd.
, Siemens Healthineers AG, Abbott, Danaher Corporation, biomérieux, QuidelOrtho Corporation, Thermo Fisher Scientific Inc., CTK Biotech, Getein Biotech, Inc., LumiraDx, Accurex, Werfen, Randox Laboratories Ltd.
, Sekisui Diagnostics, Laboratory Corporation of America Holdings, Helena Laboratories (UK) Limited, BioMedica Diagnostics, Diazyme Laboratories, Inc., HORIBA, Ltd., Sysmex Corporation, and severa.